[go: up one dir, main page]

WO2011018801A3 - Solid oral dosage form of ziprasidone - Google Patents

Solid oral dosage form of ziprasidone Download PDF

Info

Publication number
WO2011018801A3
WO2011018801A3 PCT/IN2010/000537 IN2010000537W WO2011018801A3 WO 2011018801 A3 WO2011018801 A3 WO 2011018801A3 IN 2010000537 W IN2010000537 W IN 2010000537W WO 2011018801 A3 WO2011018801 A3 WO 2011018801A3
Authority
WO
WIPO (PCT)
Prior art keywords
ziprasidone
dosage form
oral dosage
solid oral
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000537
Other languages
French (fr)
Other versions
WO2011018801A2 (en
Inventor
Deepak Murpani
Pandora Alexaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENEPHARM INDIA PVT Ltd
Original Assignee
GENEPHARM INDIA PVT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEPHARM INDIA PVT Ltd filed Critical GENEPHARM INDIA PVT Ltd
Publication of WO2011018801A2 publication Critical patent/WO2011018801A2/en
Publication of WO2011018801A3 publication Critical patent/WO2011018801A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A solid oral dosage form comprising ziprasidone or its pharmaceutically acceptable salt and cationic ion exchange resin and the process of its preparation.
PCT/IN2010/000537 2009-08-12 2010-08-12 Solid oral dosage form of ziprasidone Ceased WO2011018801A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1863MU2009 2009-08-12
IN1863/MUM/2009 2009-08-12

Publications (2)

Publication Number Publication Date
WO2011018801A2 WO2011018801A2 (en) 2011-02-17
WO2011018801A3 true WO2011018801A3 (en) 2011-04-07

Family

ID=43586593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000537 Ceased WO2011018801A2 (en) 2009-08-12 2010-08-12 Solid oral dosage form of ziprasidone

Country Status (1)

Country Link
WO (1) WO2011018801A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
US10388985B2 (en) * 2012-02-06 2019-08-20 Toyota Jidosha Kabushiki Kaisha Sulfide solid electrolyte material, battery, and producing method for sulfide solid electrolyte material
ES2441468B1 (en) * 2012-08-03 2014-11-13 Laboratorios Rubió, S.A. SOLID PHARMACEUTICAL COMPOSITION OF CATIÓNIC EXCHANGE RESIN.
CN103417541A (en) * 2013-08-22 2013-12-04 万特制药(海南)有限公司 Drug resin salt containing Ziprasidone and salt thereof and preparation method of drug resin salt

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0830864A1 (en) * 1996-09-23 1998-03-25 Eli Lilly And Company Combination therapy for treatment of psychoses
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
WO2011018801A2 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple sclerosis
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
IL245050A0 (en) Optimized fc variants, pharmaceutical compositions and medicaments comprising the same, and methods for their production
WO2010117738A3 (en) Solid state forms of sitagliptin salts
IL193340A0 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2010092090A3 (en) Novel salts of sitagliptin
ZA201201349B (en) Dihydropteridinone derivatives, preparation process amd pharmaceutical use thereof
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
SI2086945T1 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
IL203051A (en) Use of alpha-ketoglutarate for the preparation of medicaments
EP2624815B8 (en) Oral vaccine fast-dissolving dosage form using starch
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP1968943A4 (en) An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
WO2011018801A3 (en) Solid oral dosage form of ziprasidone
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2009062036A3 (en) Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
PL2291374T3 (en) Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity
IL213105A (en) Compounds, a process for the preparation thereof, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
GB2464854B (en) Process for the preparation of risperidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10808049

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10808049

Country of ref document: EP

Kind code of ref document: A2